For Research Use Only – Not for Human Consumption. For Research Use Only. Not for Human Consumption. Not for diagnostic, therapeutic or medical use. Statements have not been evaluated by the FDA.

Peptide Purity After the 2026 Compounding Shift: What HPLC, Mass Spec, and COAs Actually Show

In 2026, U.S. regulators took two notable steps that changed how several well-known research peptides sit relative to pharmacy compounding. First, FDA’s Pharmacy Compounding Advisory Committee (PCAC) reviewed nominated peptide bulk drug substances for the section 503A bulks list. Then HHS announced an interim enforcement-discretion policy for 503A compounding with a short list of those peptides while the formal 503A bulks list continues through rulemaking.

That shift has put a brighter light on a quieter question labs already care about: what does “purity” actually mean on a peptide certificate of analysis, and how does pharmacy-compounded material differ from research-use-only (RUO) supply?

This post stays on that educational line. It does not suggest that research catalog material is a substitute for a compounded prescription, and it does not claim Swift Amino products are pharmacy-grade or intended for patients.

What changed in 2026 (verified regulatory timeline)

July 23–24, 2026 — PCAC meeting

FDA’s Pharmacy Compounding Advisory Committee met to discuss nominated peptide bulk drug substances being considered for inclusion on the 503A Bulks List (the list of bulk drug substances that may be used in compounding under section 503A of the FD&C Act when they are not USP/NF monograph substances or components of FDA-approved drugs).

According to FDA’s published meeting agenda, the committee discussed:

• July 23: BPC-157, KPV, TB-500, and MOTS-c (each as free base and acetate forms)
• July 24: Emideltide (DSIP), Semax, and Epitalon (each as free base and acetate forms)

(FDA advisory committee calendar — July 23–24, 2026 PCAC meeting)

Trade and news reporting after the meeting stated that the committee recommended adding six of those peptide groups to the 503A Bulks List — BPC-157, KPV, TB-500, MOTS-c, Epitalon, and Semax — and did not recommend emideltide. PCAC votes are advisory. They are not FDA approval of a drug, and they do not by themselves place a substance on the final 503A bulks list. Final listing still requires FDA rulemaking. (NCPA, July 31, 2026; BMJ, July 28, 2026)

Category status before the PCAC votes

HHS’s later policy document notes that several of these peptides had been in Category 2 (bulk drug substances nominated for compounding that FDA has associated with significant safety concerns) from September 2023 until April 22, 2026, and that neither Category 2 placement nor removal by itself changed their status under section 503A. (HHS Enforcement Discretion Policy, Appendix B)

Late October 2026 — HHS interim enforcement discretion

In late October 2026 (Federal Register notice filed Oct. 28 and published Oct. 30), HHS issued an “Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances” (Federal Register public-inspection notice scheduled for publication October 30, 2026; Docket No. HHS-OASH-2026-0496). (Federal Register public inspection PDF, FR Doc. 2026-22192)

Under that interim policy, HHS states it does not intend to take enforcement action against a state-licensed pharmacy, federal facility, or licensed physician compounding a drug product using certain peptide bulk drug substances while the 503A bulks list is developed through rulemaking — if detailed conditions are met. The policy itself says it does not establish rights for any person and is not binding on HHS or the public. HHS may revisit it if safety signals or product-quality issues arise. (Same FR notice; full HHS policy PDF)

Appendix A peptides named in the HHS policy:

1. BPC-157
2. Epitalon
3. KPV
4. MOTS-c
5. Semax
6. TB-500

The policy pairs each with a specific chemical identity / salt form and permitted route limits in Appendix B (for example, BPC-157 acetate, TB-500 acetate, Epitalon acetate, Semax free base, KPV acetate, MOTS-c acetate). (HHS policy PDF; secondary summary: BakerHostetler, Oct 28, 2026)

What the policy is not:

• It is not FDA approval of these peptides as drugs.
• It is not a final 503A bulks-list rule (rulemaking continues).
• Legal commentary on the policy notes that it does not apply to products sold as research chemicals or dietary supplements, and that it is aimed at 503A compounding under stated safeguards. (BakerHostetler)

NCPA’s member note on October 29, 2026 likewise framed the development as enforcement discretion for 503A compounding of those six substances, with final rulemaking still pending. (NCPA, Oct 29, 2026)

Why purity talk got louder

HHS’s own justification language in Appendix B repeatedly points to lot-specific certificates of analysis from FDA-registered manufacturers — covering identity, impurity, endotoxin, microbial, residual solvent, and related results — as part of why the interim policy was framed the way it was. The policy’s testing appendix also sets out analytical expectations that compounders and API suppliers are expected to document on a COA when operating under those conditions. (HHS policy PDF — Appendix B and “Testing Standard for Peptides Used in Compounding”)

For research labs, that is a useful reminder: a peptide name on a vial is not a purity story. The story is in the methods.

What “purity” means for peptides (lab methods)

HPLC (high-performance liquid chromatography)

HPLC — often reversed-phase HPLC (RP-HPLC) — is the workhorse assay for peptide purity by area percent and for separating related impurities. On a COA you will typically see a chromatographic purity result (for example, a reported area-% for the main peak) and sometimes a separate assay against a reference standard.

In the HHS testing appendix for peptides used in compounding under the interim policy, assay is listed with HPLC / RP-HPLC based on comparison with an established quantitative reference standard, with reference to USP <621>. Impurity profiling is also expected to use orthogonal methods and to align with ICH Q3A concepts for specified / unspecified / total impurities. (HHS policy PDF)

Educational takeaway for RUO buyers: a single HPLC purity number is useful, but it is only as good as the method, the integration rules, and whether related substances were actually resolved.

Mass spectrometry (MS / LC-MS)

Mass spectrometry confirms identity by measuring mass (and, with MS/MS, sequence-related fragments). Orthogonal identity work often pairs HPLC co-elution with a reference standard and MS for monoisotopic mass; the HHS appendix also lists tandem MS sequencing, peptide mapping, and related techniques among acceptable orthogonal methods for primary-sequence confirmation. (HHS policy PDF — Table 1)

Educational takeaway: HPLC can say “one main peak”; MS helps answer “is that peak the peptide you think it is?”

Certificate of Analysis (COA)

A COA is the lot’s test report. Under section 503A generally, bulk drug substances used in compounding must be accompanied by valid certificates of analysis, and the manufacturer must be an establishment registered under section 510 of the FD&C Act. (21 U.S.C. § 353a(b)(1)(A); summarized in the HHS policy background)

The HHS interim policy goes further for the listed peptides: the COA is expected to support identity, purity, potency, and the absence of harmful contaminants such as endotoxins, heavy metals, microbial contamination, and impurities, with the original manufacturer’s facility information on the COA. (HHS policy — conditions 3–4)

When reading any peptide COA in a research setting, useful fields to check include:

• Exact chemical identity (sequence, salt form, molecular weight / formula)
• Lot / batch number and dates (manufacture, release, retest/expiry)
• Purity / assay method and result
• Related-substance / impurity results
• Residual solvents and elemental impurities (when reported)
• Appearance, water content, and storage conditions
• Which lab performed the tests

Bacterial endotoxins

Endotoxin testing (commonly limulus amebocyte lysate / LAL methods) looks for bacterial endotoxins. The HHS appendix lists bacterial endotoxins testing with reference to USP <85> as a critical quality attribute especially relevant to injectable dosage forms. (HHS policy PDF)

Bioburden, microbial limits, and sterility concepts

The same appendix lists bioburden / microbial enumeration expectations (USP <61>, <62>, <1111>) for bulk drug substance characterization under the compounding testing standard. Finished sterile compounded preparations are a separate pharmacy quality topic: sterile compounding practice, environmental controls, and sterility testing of finished units sit under pharmacy compounding standards and state board oversight, not under an RUO catalog claim. This article does not walk through clinical compounding procedures. (HHS policy PDF)

Pharmacy-compounded vs research-grade: different channels

Sources for the left column: HHS policy PDF; FR public-inspection notice.

Swift Amino’s lane is the right-hand column. Our catalog is research-use-only. That is a different regulatory and quality conversation from a state-licensed pharmacy compounding a patient-specific preparation under 503A and the interim HHS conditions. RUO material should not be treated as a pharmacy product, and pharmacy compounding should not be confused with an RUO vial.

Practical reading tips for a research COA

1. Match the identity, not just the trade nickname. Sequence, salt form (acetate vs free base), and molecular weight matter — the 2026 policy discussions treated forms separately.
2. Ask which method produced the purity number. HPLC area-% and a quantitative assay against a reference standard are not always the same claim.
3. Look for orthogonal identity support. MS or LC-MS alongside chromatography is stronger than either alone.
4. Read impurity and contaminant fields when present. Related peptides, residual solvents, elemental impurities, endotoxin, and microbial results answer different questions.
5. Keep channels straight. A compounding policy discussion does not convert an RUO catalog item into a compounded drug, and it does not authorize human use of research materials.

Bottom line

The July 2026 PCAC recommendations and the October 2026 HHS interim enforcement-discretion policy are real regulatory developments for a short list of peptide bulk substances in the pharmacy compounding channel. They are not a final 503A bulks-list rule, not FDA drug approvals, and not a change to the meaning of research-use-only supply.

What they do reinforce for anyone who works with peptides in a lab is older and simpler: purity is a measured claim. HPLC, mass spectrometry, endotoxin and microbial data, and a lot-specific COA are how that claim is inspected — whether the material is destined for a compounding file under pharmacy rules or for a research bench under RUO terms.

Sources (selected)

1. FDA — July 23–24, 2026 Meeting of the Pharmacy Compounding Advisory Committee
2. HHS — Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances (policy PDF)
3. Federal Register public inspection — FR Doc. 2026-22192 (scheduled Federal Register publication October 30, 2026)
4. NCPA — FDA advisory committee nominates six peptides for pharmacies to compound (July 31, 2026)
5. NCPA — FDA grants enforcement discretion to compounding six peptides (October 29, 2026)
6. BakerHostetler — HHS Issues Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances (October 28, 2026)
7. BMJ — Peptides: US advisory committee recommends six for FDA “compounding list” (July 28, 2026)